

**Supplementary Table S4.** Summary of Biomarker Changes in the Gastric Cancer Cohort

Analytes	Cycle 2 Day 1			Cycle 3 Day 1			Cycle 4 Day 1		
	Median % change <sup>a</sup>	P-value	Adjusted P-value	Median % change <sup>a</sup>	P-value	Adjusted P-value	Median % change <sup>a</sup>	P-value	Adjusted P-value
6Ckine	4.7	2.9E-01	4.5E-01	8.8	<5.0E-02	1.2E-01	3.9	1.3E-02	4.2E-02
ANG-1	6.7	1.1E-01	2.2E-01	2.6	5.4E-01	6.8E-01	-7.4	3.8E-01	5.4E-01
ANG-2	4.7	2.0E-01	3.2E-01	20.4	1.5E-04	1.1E-03	12.9	3.2E-04	2E-03
BAFF	38.5	2.0E-07	3.6E-06	54.8	5.7E-07	7.7E-06	57.3	3.9E-07	5.8E-06
BDNF	0	3.3E-01	5.0E-01	-3.4	9.9E-01	9.9E-01	-5.0	9.2E-01	9.5E-01
BLC	0	7.4E-01	8.4E-01	10.8	2.6E-01	4.1E-01	0	1.3E-01	2.3E-01
CA-15-3	-7.0	4.5E-02	1.1E-01	-4.6	9.1E-01	9.5E-01	0	5.7E-01	7.0E-01
CA-9	-4.8	9.8E-01	9.9E-01	-7.4	4.2E-01	5.6E-01	17.6	1.8E-01	3.0E-01
<b>Collagen IV</b>	<b>30.7</b>	<b>1.1E-06</b>	<b>1.4E-05</b>	<b>45.5</b>	<b>4.1E-05</b>	<b>3.4E-04</b>	<b>65.5</b>	<b>3.8E-06</b>	<b>4.1E-05</b>
Decorin	5.3	4.6E-01	6.0E-01	0	6.4E-01	7.6E-01	0	8.7E-01	9.3E-01
EGF	-2.3	9.8E-01	9.9E-01	-7.0	8.0E-01	8.7E-01	-4.7	9.1E-01	9.5E-01
EGFR	0	7.2E-01	8.3E-01	4.0	4.6E-01	6.0E-01	4	1.7E-01	3.0E-01
<b>Endoglin</b>	<b>3.2</b>	<b>4.2E-01</b>	<b>5.6E-01</b>	<b>3.2</b>	<b>1.8E-01</b>	<b>3.0E-01</b>	<b>11.8</b>	<b>2.8E-03</b>	<b>1.3E-02</b>
FABP, adipocyte	22.2	2.8E-07	4.5E-06	27.7	8.8E-06	8.4E-05	21.1	4.5E-04	2.8E-03
Factor VII	-2.1	9.7E-01	9.9E-01	-2.7	6.4E-01	7.6E-01	-2.9	8.9E-01	9.4E-01
HB-EGF	0	1.1E-01	2.1E-01	3.7	4.2E-01	5.6E-01	-3.7	8.9E-01	9.4E-01
Hepsin	3.1	2.9E-01	4.6E-01	9.4	6.5E-03	2.6E-02	4.9	6.2E-02	1.4E-01
HER-2	3.8	3.7E-01	5.3E-01	14.3	2.3E-03	1.1E-02	16.3	4.2E-05	3.4E-04
HGF receptor	7.3	1.7E-02	5.1E-02	9.1	2.1E-02	6.2E-02	9.5	1.1E-01	2.1E-01
<b>ICAM1</b>	<b>8.1</b>	<b>6.9E-03</b>	<b>2.7E-02</b>	<b>14.5</b>	<b>1.5E-06</b>	<b>1.7E-05</b>	<b>8.6</b>	<b>1.1E-03</b>	<b>6.4E-03</b>
IFN-gamma	-31.3	1.3E-01	2.4E-01	7.1	7.6E-01	8.4E-01	-22.2	7.6E-01	8.4E-01
IGFBP-1	42.9	2.2E-03	1.1E-02	75.0	3.4E-05	3.0E-04	50.0	2.2E-03	1.1E-02
IGFBP-2	16.5	6.0E-03	2.4E-02	17.4	1.0E-02	3.7E-02	2.6	1.4E-01	2.5E-01
IL-1 beta	0	9.3E-01	9.5E-01	0	4.1E-01	5.6E-01	0	4.0E-01	5.6E-01
IL-12p40	0	3.2E-01	4.8E-01	0	6.8E-01	7.9E-01	0	6.5E-01	7.7E-01
IL-13	16.7	1.7E-02	5.1E-02	6.3	3.1E-01	4.7E-01	0	4.2E-01	5.6E-01
IL-18	17.7	4.9E-04	3.0E-03	32.0	1.1E-03	6.4E-03	15.6	1.5E-02	4.9E-02
IL-18bp	9.1	1.6E-02	5.0E-02	13.6	1.6E-04	1.1E-03	19.8	4.7E-05	3.6E-04
IL-1ra	0	1.8E-01	3.0E-01	7.8	1.7E-02	5.1E-02	7.4	4.3E-02	1.1E-01
IL-8	-17.4	3.3E-02	8.6E-02	-29.2	1.6E-01	2.8E-01	0	5.4E-01	6.8E-01
IP-10	-0.4	7.7E-01	8.5E-01	5.9	8.6E-02	1.8E-01	0	4.0E-01	5.6E-01
ITAC	25.0	2.3E-02	6.4E-02	4.3	1.2E-01	2.2E-01	11.8	3.4E-01	5.0E-01
KLK-5	17.4	1.3E-03	6.8E-03	23.3	5.6E-03	2.3E-02	23.3	1.9E-04	1.3E-03
KLK-7	-6.7	8.2E-02	1.7E-01	-14.3	3.6E-01	5.2E-01	-16.3	5.6E-02	1.3E-01
MCP-1	-20.4	5.7E-02	1.3E-01	-16.5	9.1E-02	1.9E-01	-8.9	9.7E-02	1.9E-01
MIF	-16.1	1.6E-01	2.8E-01	22.6	3.5E-01	5.1E-01	7.5	3.6E-01	5.2E-01
MIG	-17.3	3.5E-02	9.0E-02	-10.7	5.9E-01	7.2E-01	-13.2	1.0E-01	2.0E-01
MIP-1 beta	9.0	6.9E-01	8.0E-01	6.7	9.5E-02	1.9E-01	0	6.6E-01	7.7E-01
MIP-3 beta	-7.8	1.4E-01	2.5E-01	6.3	1.8E-01	3.0E-01	-0.3	8.0E-01	8.7E-01
MMP-3	9.1	1.1E-02	3.8E-02	15.8	2.6E-02	7.0E-02	4.9	7.0E-02	1.5E-01
PDGF-BB	6.5	7.4E-02	1.6E-01	0.3	5.6E-01	6.9E-01	-3.0	7.0E-01	8.1E-01
<b>PECAM1</b>	<b>9.8</b>	<b>7.0E-06</b>	<b>7.1E-05</b>	<b>20.0</b>	<b>4.5E-08</b>	<b>1.5E-06</b>	<b>22.4</b>	<b>2.0E-07</b>	<b>3.6E-06</b>
Prostasin	0.7	5.1E-01	6.6E-01	5.4	4.7E-01	6.1E-01	3.1	5.2E-01	6.7E-01
SCF	0	8.0E-01	8.7E-01	0	2.6E-01	4.1E-01	-11.3	7.4E-01	8.4E-01
SDF-1	-4.9	1.1E-02	3.8E-02	-5.2	1.1E-02	3.8E-02	-5.9	8.8E-03	3.3E-02
SP-D	5.0	2.2E-01	3.6E-01	15.4	4.5E-03	2.0E-02	1.3	3.0E-01	4.6E-01
<b>TIE2</b>	<b>23.8</b>	<b>5.9E-08</b>	<b>1.5E-06</b>	<b>31.9</b>	<b>9.7E-09</b>	<b>3.9E-07</b>	<b>34.1</b>	<b>6.7E-08</b>	<b>1.5E-06</b>
TN-C	69.8	3.2E-10	5.2E-08	90.7	4.5E-09	2.8E-07	63.3	5.2E-09	2.8E-07

Analytes	Cycle 2 Day 1			Cycle 3 Day 1			Cycle 4 Day 1		
	Median % change <sup>a</sup>	<i>P</i> -value	Adjusted <i>P</i> -value	Median % change <sup>a</sup>	<i>P</i> -value	Adjusted <i>P</i> -value	Median % change <sup>a</sup>	<i>P</i> -value	Adjusted <i>P</i> -value
uPAR	5.8	8.3E-02	1.7E-01	12.5	3.3E-03	1.5E-02	13.6	1.2E-03	6.4E-03
VEGF	14.2	3.0E-02	7.9E-02	16.8	6.7E-02	1.5E-01	8.3	7.1E-02	1.5E-01
VEGF-D	6.6	6.1E-02	1.4E-01	9.7	2.3E-02	6.4E-02	22.6	4.6E-02	1.1E-01
<b>VEGFR1</b>	<b>40.4</b>	<b>5.4E-03</b>	<b>2.3E-02</b>	<b>36.7</b>	<b>9.6E-03</b>	<b>3.5E-02</b>	<b>36.7</b>	<b>1.5E-02</b>	<b>4.9E-02</b>
<b>VEGFR2</b>	<b>3.4</b>	<b>5.5E-01</b>	<b>6.8E-01</b>	<b>-3.7</b>	<b>9.1E-01</b>	<b>9.5E-01</b>	<b>-4.0</b>	<b>6.1E-01</b>	<b>7.4E-01</b>
<b>VEGFR3</b>	<b>4.3</b>	<b>3.1E-01</b>	<b>4.7E-01</b>	<b>12.5</b>	<b>2.9E-02</b>	<b>7.8E-02</b>	<b>9.1</b>	<b>2.5E-02</b>	<b>6.7E-02</b>

Endothelial/vasculature-associated markers are indicated in **bold text**. *P*-values were based on 2-sided 1-sample Wilcoxon signed rank test, and the adjusted *P*-values were adjusted for false discovery rate control by the number of biomarkers analyzed at each time point ( $n = 54$ ). Biomarkers with  $P < 0.05$  at any time point are considered significant (highlighted in gray). *P*-values are expressed in scientific notation, ie, E-01 is  $10^{-1}$ , therefore the value 5.1E-01 would equal 0.51.

<sup>a</sup>From baseline.

C, cycle; d, day; FDR, false discovery rate.